Works about PROTEIN-tyrosine kinase inhibitors

Results: 5000
    1
    2
    3

    Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 13, p. 1, doi. 10.1002/cncr.35963
    By:
    • Giai, Valentina;
    • Rosso, Tiziana;
    • Castagnetti, Fausto;
    • Pregno, Patrizia;
    • Bonifacio, Massimiliano;
    • Capodanno, Isabella;
    • Tiribelli, Mario;
    • Stagno, Fabio;
    • Caocci, Giovanni;
    • Gozzini, Antonella;
    • Luciano, Luigiana;
    • Galimberti, Sara;
    • Bocchia, Monica;
    • Patriarca, Andrea;
    • Lanzarone, Giuseppe;
    • Martino, Bruno;
    • Guella, Anna;
    • Scortechini, Anna Rita;
    • Fava, Carmen;
    • Fozza, Claudio
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients.

    Published in:
    Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-05828-x
    By:
    • Barakat, Eman M. F.;
    • Kohla, Mohamed;
    • Dabees, Hossam;
    • Shousha, Hend Ibrahim;
    • Moustafa, Ehab F.;
    • El-Kassas, Mohamed;
    • Aziz, Mona Shoukry;
    • Elkhateeb, Eman;
    • Abdelaziz, Ashraf Omar;
    • Abdelmalek, Mohamed Omar;
    • Azmy, Aly;
    • Tawheed, Ahmed;
    • Aboganob, Walaa Mosaad;
    • Taha, Hossam;
    • Lithy, Rania;
    • Radwan, Ahmed;
    • Ghoraba, Dalia;
    • Sayed, Hamdy;
    • Nassief, Anwar;
    • Elhelbawy, Mostafa
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32

    Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.

    Published in:
    Oncologist, 2025, v. 30, n. 6, p. 1, doi. 10.1093/oncolo/oyaf138
    By:
    • Beckermann, Kathryn E;
    • Shah, Neil J;
    • Campbell, Matthew T;
    • Haas, Naomi B;
    • Nelson, Ariel;
    • Ornstein, Moshe C;
    • Mao, Shifeng;
    • Keshava-Prasad, Holavanahalli S;
    • Hammers, Hans;
    • Gao, Xin;
    • Gourdin, Theodore;
    • George, Saby;
    • Hoimes, Christopher J;
    • Hussain, Arif;
    • Jonasch, Eric;
    • Rini, Brian I;
    • Voss, Martin H
    Publication type:
    Article
    33
    34
    35
    36

    New and Convergent Synthesis of Deucravacitinib.

    Published in:
    Organic Preparations & Procedures International, 2025, v. 57, n. 4, p. 357, doi. 10.1080/00304948.2025.2480315
    By:
    • Liu, Wei;
    • Mao, Yongjun;
    • Chen, Junhao;
    • Yan, Xinze
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44

    Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma.

    Published in:
    Acta Neuropathologica Communications, 2025, v. 13, n. 1, p. 1, doi. 10.1186/s40478-025-02068-y
    By:
    • Lin, Benjamin;
    • Shelton, Abigail K.;
    • Smithberger, Erin;
    • Ziebro, Julia;
    • Skinner, Kasey R.;
    • Bash, Ryan E.;
    • Kirkman, Richard;
    • Stamper, Allie;
    • Butler, Madison;
    • Flores, Alex;
    • Angus, Steven P.;
    • East, Michael P.;
    • Cloughesy, Timothy F.;
    • Nathanson, David A.;
    • Berens, Michael E.;
    • Sarkaria, Jann N.;
    • Binder, Zev A.;
    • O'Rourke, Donald M.;
    • Howton, Timothy C.;
    • Lasseigne, Brittany N.
    Publication type:
    Article
    45
    46
    47
    48
    49
    50